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12 months. Chemotherapy may be added along with radiation in the recurrent setting.
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patients in whom it is feasible. In patients in whom surgery is not feasible, re-irradiation must be
evaluated as a therapeutic option especially in patients with limited volume recurrence.
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Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer globally [1]. The advances in surgical and
radiotherapy techniques have contributed tremendously
toward improved outcome with less morbidity in these patients
[2]. Despite the advances in the last two decades, 35–40% of
patients recurs locally or loco-regionally and poses a signiﬁ-
cant health burden. Second primary cancers in the head and
cancer region further add to this burden, which can be as high
as 20–25% in a long term [3]. The treatment of recurrent/sec-
ond primary HNSCC is always challenging and is associated
with signiﬁcant morbidity [4]. A balance has to be achieved
between local control and treatment related morbidity and
mortality. Salvage surgery alone has yielded dismal results as
has systemic chemotherapy alone [4,5–8]. Median survival with
both these approaches has ranged from 5 to 9 months. In addi-
tion, many patients are found unsuitable for surgery because
of disease extent or morbidity associated with such approach.
Re-irradiation of such cases has been tried in the recent prac-
tice with promising results. Understanding of the molecular
biology and genetic aberrations has paved for newer targeted
drugs and are being increasingly tried for the treatment of such
cases. However, there is limited prospective data about the
management of recurrent/second primary HNSCC
(rHNSCC). Hence, management of these tumors varies widely
across institutes and based on local perception, available
resource. The non-availability of prospective data also pre-
cludes comparing one modality to the other and ﬁnds the opti-
mum based treatment option. In this review we intend to look
into current status of re-irradiation for the treatment of recur-
rent/second primary HNSCC (rHNSCC).
Search methodology
We performed a comprehensive search of the PubMed, SCO-
PUS and Google Scholar with the following MesH terms:
‘‘reirradiation in head and neck cancer, radiation in recurrent
head and neck cancer, reirradiation AND recurrent head and
neck cancer AND treatment, survival” to ﬁnd all possible pub-
lications pertaining to rHNSCC. We also conducted a detailPlease cite this article in press as: Benson R et al. Re-irradiation for head and neck s
10.1016/j.jnci.2016.07.002search of the references in the available article to retrieve miss-
ing articles and conducted a hand search in Google to ﬁnd any
possible publication. After a thorough search the duplicates
were removed and the remaining articles were looked into
detail.
Investigations
As patients with local or nodal recurrence would undergo a
salvage surgery or salvage re-irradiation it is important to rule
out any other site of disease that is not evident clinically. An
indirect laryngoscopy and upper gastrointestinal endoscopy
must be done in all patients and suspected abnormal areas
must be biopsied. A contrast enhanced magnetic resonance
imaging (MRI) of the head and neck may be superior to con-
trast enhanced computed tomography (CT) depending on the
tumor subsite and tumor extensions. Soft tissue delineation
of the disease may be better appreciated in an MRI than a
CT. In addition the perfusion and diffusion-weighted MRI
helps in differentiating recurrent cancer from post radiation
changes [9]. PET scan also is of great help in this scenario
and is associated with a high predictive value in patients with
recurrence post chemoradiation [10].
The need for a re-biopsy is sometimes debated in a recur-
rent head and neck cancer patient. It may be avoided in some
patients in whom recurrence occurred early and have a diffuse
metastatic disease that is clinically correlating with the natural
course of the disease. This is particularly important in these
patients due to the ﬁeld cancerization phenomenon that occurs
in head and neck cancers [11]. It is also of signiﬁcance as the
patient might have developed a radiation induced second pri-
mary which is usually a sarcoma, which should be salvaged
surgically [12,13].
Prognostic factors in recurrent Head and neck squamous cell
carcinoma
Prognosis with salvage treatment depends on disease related
factors or treatment related factors. Balancing toxicity and dis-
ease control becomes an important issue in re-irradiation.
Disease related factors are site of recurrence, previous responsequamous cell carcinoma, J Egyptian Nat Cancer Inst (2016), http://dx.doi.org/
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papilloma virus (HPV) status [5,6]. Treatment related factors
include usage of conformal radiation therapy, dose of reirradi-
ation, concurrent chemotherapy usage, salvage surgery and
radiation volume [7,8,14]. Patient related factors include age,
performance status, comorbidities, organ dysfunction from
previous treatment, feeding tube dependency, tracheostomy
and soft tissue defect [15–18].
Tanvetyanon et al. in a retrospective series of 103 patients
found comorbidity and organ dysfunction as independent pre-
dictors of survival. Reasons attributed were both factors may
lead to suboptimal cancer directed therapy and increase risk
of death from cancer related causes and may cause death
due to non-cancer related causes as well. Other factors that
had prognostic implications were T stage, tumor bulk, re-
irradiation dose, time interval between previous radiation
and current. [19]. In a similar series of 79 patients aged less
than 50 years, a disease free interval of two years or more pos-
itively inﬂuenced survival [20]. Choe et al. evaluated phase 1
and phase 2 protocols of 166 patients who underwent chemo
radiation in recurrence. Prognostic factors for overall survival
were previous chemoradiotherapy (CTRT), surgery before
CTRT, re-irradiation and RT interval. Patient who had previ-
ously received CTRT had dismal outcomes. Reason attributed
was aggressive tumor biology and resistant clonogens [21].
General treatment approach
Various available treatment options should be discussed with
the patients with particular emphasis of treatment outcome
and toxicity. Surgical salvage should be attempted whenever
possible as surgical salvage in recurrent setting has been found
to be an independent prognostic factor [4]. The patients must beFigure 1 Proposed treatment approach
Please cite this article in press as: Benson R et al. Re-irradiation for head and neck s
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mance status, age of the patient, site of recurrence, volume of
recurrence, disease free interval, and presence of severe co-
morbidity. The sub-sites like oral cavity and limited nodal
recurrence are ideal candidates for a surgical salvage. Speciﬁc
issues related to surgery in recurrent setting like wound healing,
organ dysfunction, dependency on feeding tube and increased
blood loss during surgery must also be kept in mind before tak-
ing a patient for salvage surgery. Post radiation ﬁbrosis in the
neck also makes surgical salvage difﬁcult in some cases.
The availability of modern surgical techniques like trans-
oral robotic surgery (TORS), trans-oral microsurgical
approaches have made surgery a viable option in oropharyn-
geal cancers with small disease volume. Those patients who
are found not suitable for surgery may be evaluated for
re-irradiation. But here also careful patient selection is the
key to optimize outcomes. Those who are not suitable for
either may be given systemic chemotherapy with a palliative
intent. A treatment approach to a patient with localized recur-
rent HNSCC is given in Fig. 1.
Re-irradiation in recurrent/second head and neck cancers
Re-irradiation has long remained an unpopular treatment
option because of variety of reason including fear of excessive
toxicity, unpredictable dose delivery beyond the normal tissue
tolerance and non-availability of imaging modality. With
advent of sophisticated radiotherapy techniques like stereotac-
tic radiotherapy, image guided radiotherapy and intensity
modulated radiotherapy, re-irradiation rHNSCC has gained
momentum. Re-irradiation alone or in combination with
chemotherapy can be offered in patients not suitable for sur-
gery. In addition, reirradiation can also be offered for patientsfor a recurrent head and neck cancer.
quamous cell carcinoma, J Egyptian Nat Cancer Inst (2016), http://dx.doi.org/
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subsequent segments we will discuss about patient selection
criteria for re-irradiation, the acceptable dose fractionations,
role of brachytherapy, target volume deﬁnitions, the role of
concurrent chemotherapy, toxicity prediction, prevention, mit-
igation and treatment of radiation toxicity.
Patient selection criteria for re-irradiation
There are a number of patient related, tumors related and pre-
vious treatment related factors that predict prognosis after
re-irradiation. Charlson co-morbidity index, ACE grading –
27 [19], feeding tube dependency, presence of tracheostomy,
presence of skin necrosis, Karnofsky performance status
(KPS) and age [22] are patient related factors that deﬁne prog-
nosis and help in selecting patients for re-irradiation.
Smaller tumor volume(<221 ml), nasopharyngeal and
laryngeal recurrence, longer time interval of recurrence
(>16 months) are some of the tumor related factors that pre-
dict favorable prognosis compared to patients with larger vol-
ume, non-laryngeal primary, and early recurrence [20,22].
Patients treated with conformal techniques and for smaller vol-
umes in initial treatment are expected to fare better with lesser
toxicity compared to conventional treatment [20,22]. Patients
treated with conformal techniques and for smaller volumes
in initial treatment are expected to fare better with lesser tox-
icity compared to patients treated with conventional tech-
nique. Patients who received chemotherapy as part of initial
treatment are associated with increased toxicity [21]. Not many
molecular factors have been validated for selecting patients for
re-irradiation. While treating patients with hypofractionated
radiation, the risk of carotid blow out should be considered.
Only patients with <180 degree encasement of carotid artery
on imaging and absence of ulceration can be taken up [23].
A carotid blow-out syndrome (CBOS) index has been con-
structed by a retrospective analysis of cases receiving hypofrac-
tionated RT to help select patients.
In the post-operative setting patients with margin positive
disease, extracapsular nodal spread, deeply inﬁltrating tumors
(>1 cm), rT4 disease in larynx and nodes >3 cm in size are to
be considered for re-irradiation [24,25]. Point should be made
that the indications of postoperative re-irradiation are less dis-
cussed. Janot et al. did not include patients with R1 resection.
However, from all other series it appears that re-irradiation
should be delivered for margin positive resection and ECE.
Rest of the factors should play an important role to tradeoff
between toxicity and beneﬁt of re-irradiation.
Dose fractionations for re-irradiation
Dose fractionation is critical in eradiating the tumor cells.
There are different radiation schedules-hyper fractionation,
accelerated fractionation and hypo fractionation. Radiation
in hyper fractionation is delivered in small dose per fraction
with two or three fractions delivered every day to achieve a
higher biologically effective dose to the tumor when the a/b
ratio for tumor cells is greater than that for the dose-
limiting, late-responding normal tissue. Hyper fractionation
also induces radio-sensitization through cell-cycle redistribu-Please cite this article in press as: Benson R et al. Re-irradiation for head and neck s
10.1016/j.jnci.2016.07.002tion, whereas, accelerated radiation aims to complete the
scheduled radiation before the accelerated repopulation kicks
off following a lag phase of nearly 4 weeks. An incremental
dose of 0.6 Gy is required after this to counter the accelerated
repopulation to achieve tumor control. Based on these princi-
ples, hyper fractionation would be the preferred approach for
re-irradiation because of improved sparing of late responding
tissues with equal total dose. There is a considerable debate
regarding the optimal dose fractionation in re-irradiation. A
dose of >72 Gy biological equivalent dose (BED) or equiva-
lent dose 2 Gy (EQD2) of 60 Gy has been shown to have
favorable OS in certain series compared to less than 72 Gy
[22]. The incidence of carotid blowout was higher when
1.5 Gy twice daily fractionation ﬁve days a week on alternate
weeks or delayed accelerated hyper fractionation was used
compared to 2 Gy daily or 1.2 Gy twice daily ﬁve days a week
[26]. Hypo-fractionation 48 Gy BED in ﬁve fractions has pro-
vided comparable results in terms of PFS and OS in a small
series but with increased late toxicity. Certain criteria like
CBOS index have been created to deﬁne suitable patients for
hypo fractionation [23]. So the most acceptable and effective
dose fractionation seems to be 60 Gy in 30 fractions over six
weeks or 64 Gy in 54 fractions twice daily over 5.5 weeks.
The ﬁnal dose prescribed must also take into account the tech-
nique used, volume of recurrence, dose received by vital struc-
tures during previous irradiation. Hypo-fractionation can be
considered with the caveat of increased risk of late toxicity.
Hypo-fractionation is useful in small volume recurrence far
from the spinal cord and carotids.Target volume definition for re-irradiation
After radiation and surgery, normal lymphatic ﬂow gets dis-
rupted. So, in recurrent tumors of head and neck lymph node
metastases do not follow the expected pattern based on loca-
tion and size of primary. Lymphoscintigraphy studies have
shown that in around two thirds of cases the lymph ﬂow is
altered post-radiation [27]. Irradiating uninvolved nodal
region leads to increased volume of irradiation and higher tox-
icity. Recurrence can occur only in primary, only in nodes or in
both nodes and primary. If recurrence is only in the primary,
the target volume is deﬁned as gross tumor plus a 0.5–1 cm
margin to form clinical target volume (CTV). If only in nodes,
the target volume will include the involved nodal level or in few
cases only the gross node with a 0.5–1 cm margin [20]. The
need to use a margin to account for microscopic disease has
been questioned as most recurrences that have occurred after
re-irradiation have been in ﬁeld recurrences [28].
The target delineation should include the use of imaging
modalities of MRI and PET. PET integration in planning
has demonstrated to shift the location of GTV when compared
to CT alone because of clearer differentiation with ﬁbrosis and
post treatment changes [29,30]. MRI will help in identifying
ﬁbrosis and identifying carotid vessel ulceration and encase-
ment. It is difﬁcult to comment on volumes to be treated when
both primary and nodes are involved and should be left to the
physician’s discretion. The re-recurrence is most commonly
seen in the areas of initial GTV. Hence, elective local or nodal
irradiation is not beneﬁcial [20].quamous cell carcinoma, J Egyptian Nat Cancer Inst (2016), http://dx.doi.org/
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As re-irradiation may be associated with higher toxicity, more
so with concurrent chemotherapy it is advisable to use the best
conformal technique. Compared to conventional technique
intensity modulated radiotherapy (IMRT) enables delivery of
conformal dose to the target, but at the risk of increased inte-
gral dose. Lee et al. reported higher loco regional failure with
non-intensity modulated techniques [8]. The use of image guid-
ance during radiation delivery help in reducing the margins
given for the planning target volume and thus must be used.
Proton therapy also needs to be evaluated due to its physical
property of the Bragg peak. Point should be made that proton
therapy is not necessarily superior in all patients [31]. But, for
eligible patients proton therapy may impart long term disease
control. Hayashi et al. in a series of 34 patients combined
intra-arterial chemotherapy with proton therapy. They
reported encouraging 1-year and 2-year LC rates of 77% and
60% [32]. In another recent report Romesser et al. reported lim-
ited toxicity with proton beam reirradiation. The authors
reported acute grade 3 or greater toxicity in the form of mucosi-
tis (9.9%), dysphagia (9.1%), esophagitis (9.1%), and dermati-
tis (3.3%) [33]. Thus the best conformal technique available
must be used for re-irradiation with the use of image guidance.
Dose constrains for the organs at risk
There is paucity of data regarding optimum dose constraints
for re-irradiation. So, whenever dose constraints are discussed
it is based on some retrospective literature only discussing tox-
icity proﬁle for a given set of patients. Dose constrains for re-
irradiation must be individualized on a case to case basis
depending on the previous dose fractionation used, and time
since previous irradiation. In a study by Zwiker et al. the risk
for xerostomia was signiﬁcantly higher for cumulative mean
doses of P45 Gy to parotid glands [34]. Spinal cord is one
of the most critical organs at risk during radiation. As these
patients already have radiation up to 70 Gy the spinal cord
receives up to the maximum tolerable dose by then and limits
the further option of dose delivery. In this context Schultheiss
et al. made an import revelation that after an initial dose of
45 Gy, 50% recovery happens for an elapsed period of two
years [35]. Nieder et al. in a literature review found small risk
of myelopathy after 6135.5 Gy [BED] when the interval is not
shorter than 6 months and the dose of each course is 698 Gy
[36]. Sminia et al. also shared similar view of spinal cord recov-
ery after primary radiation and cumulative irradiation dose
applied to the spinal cord can vary between 125 and 172%
of the BED tolerance [37]. They also found that keeping cumu-
lative maximum dose to the spinal cord of 53 Gy and 63 Gy to
the brain stem is safe in patients with re-irradiation. Similarly a
study by Yamasaki et al. had found that re-irradiation dose to
spinal cord and brainstem, below 60 Gy was safe without any
long term neurological complications [28]. The cumulative
mandible below 70 Gy, and two-thirds laryngeal dose below
50 Gy may be safe [38]. Chua et al. in a phase II study for
recurrent nasopharyngeal carcinoma used the following dose
constraints: 10 Gy 6 10% for brainstem, 4 Gy 6 5% for spinal
cord, 8 Gy 6 5% for optic nerve and chiasm, 10 Gy 6 5% for
orbit, and 10 Gy 6 10% for temporal lobe. The authors
reported modest late toxicity with these dose constraints ofPlease cite this article in press as: Benson R et al. Re-irradiation for head and neck s
10.1016/j.jnci.2016.07.0027% and 25% grade III toxicity at 6 and 12 months [39]. But
the ﬁnal dose constrain for an IMRT must be personalized
on a patient to patient basis.Brachytherapy for re-irradiation
Brachytherapy allows for a very conformal radiation if recur-
rence is conﬁned to primary or single lymph node. But per-
forming brachytherapy may be difﬁcult in a re-irradiation
setting. Fibrosis of neck may make placement of needles difﬁ-
cult. Often the location of recurrence like larynx and
hypopharynx is inaccessible to brachytherapy. Trismus due
to prior radiation and disease per se makes placement of nee-
dles difﬁcult in anterior and base of tongue. If recurrence is
close to bones like mandible, the high dose per fraction and
dose rate in HDR brachytherapy may lead to osteoradionecro-
sis. The risks may thus outweigh the beneﬁts of the procedure
in a patient who has limited survival.
There are very few studies that have used brachytherapy in
a reirradiation setting. In a phase I/II reirradiation study by
Martinez–Monge et al. 25 patients were treated with peri-
operative high dose rate brachytherapy (4 Gy twice daily  8
(32 Gy) for R0 resections and 4 Gy twice daily  10 (40 Gy)
for R1 resections) [40]. The authors reported a 4 year local
control rate of 85.6% and OS of 46.4%. However 40%
(n= 10) developed RTOG grade 3 or higher toxicity. Strnad
et al. evaluated pulsed dose rate brachytherapy with
chemotherapy or hyperthermia for rHNSCC [41]. The authors
reported improved local control when PDR brachytherapy
was used in combination with systemic chemotherapy.Post-operative reirradiation
Re-irradiation after salvage surgery is required for patients
with adverse pathological features. Indications for reirradia-
tion after salvage surgery are extra nodal spread, positive sur-
gical margins, and/or other risk factors like close margin,
lymphovascular space invasion [24,42]. Kasperts et al. in a
prospective study of 39 patients reported 3 year loco regional
control and overall survival 74%, 44%respectively, however
at the cost of higher toxicity [42]. Janot et al. randomly
assigned 130 patients with head and neck cancer treated with
salvage surgery to full-dose reirradiation combined with
chemotherapy or to observation. The authors reported signif-
icantly improved disease free survival but OS was not different
between two arms. The authors also report higher rate of treat-
ment related toxicity. Unfortunately, the authors do not men-
tion about techniques of radiation. Radiation technique would
be of importance in such cases for limiting the toxicity. Inter-
estingly, 37% patients in the reirradiation arm had P3 node
positive compared to 12% in the observation arm. It appears
such high risk patients may have contributed to larger volume
of radiation and death secondary to toxicity [24].
Systemic therapy with re-irradiation – feasibility and outcomes
A number of systemic agents like paclitaxel, carboplatin, doc-
etaxel, erlotinib, cisplatin, hydroxyurea and adenoviral vector
expressing TNF alpha have been integrated with re- irradia-
tion [42–48]. The logic is to eradicate microscopic disease thatquamous cell carcinoma, J Egyptian Nat Cancer Inst (2016), http://dx.doi.org/
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6 R. Benson et al.may be left out as the irradiation is to a limited region and also
to act as a radio sensitizer. The use of chemotherapy has not
prolonged survival signiﬁcantly in many series of reirradiation.
A large number of patients receiving re-irradiation would have
also received chemotherapy either concurrently or in the
neoadjuvant setting for the primary disease. The use of
chemotherapy in the primary setting may have led to resistance
by increased efﬂux of drugs by tumor cells, improved DNA
repair mechanisms and increased glutathione production
(GSH). All these may contribute to decreased effectiveness of
chemotherapy along with radiation in the recurrent setting.
Also drugs like cisplatin may also lead to cumulative toxicity
mainly the neuropathy. The speciﬁc issue whether addition
of chemotherapy adds to survival in patients undergoing re-
irradiation for head and neck cancer is not well addressed in
studies. But, it would be logical to use a chemotherapy which
has a different mechanism of action and minimal cross resis-
tance with the drug used in the primary disease while treating
recurrent disease. A summary of various chemo-re-irradiation
trials are summarized in Table 2 [25,42–47].T
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Toxicity is one of the main concerns during re-irradiation for
a recurrent HNSCC. Acute mucositis is the predominant
adverse reaction during radiation which may be more severe
with addition of chemotherapy. This can be reduced to a
great extent using more conformal techniques for re-
irradiation thus reducing the amount of mucosa coming in
the radiation ﬁeld. Usually the acute mucositis subsides and
is manageable. But what is more worrisome is the late toxic-
ity. The late toxicity ranges from the dreaded carotid blow
out to the chronic xerostomia. In our experience 30% patients
suffered from acute grade 3 or worse toxicity. In our series 7
patients suffered from grade 3 skin toxicity, 12 patients suf-
fered from grade 3 mucosal toxicity, and 5 patients had grade
3 laryngitis. However, there was no death because of toxicity
or carotid blow out. However, point should be made nearly
50% patients receive re-irradiation by conventional technique
[20].
The incidence of carotid blow out may be as high as 5%
[6]. This is a life threatening complication and can be
avoided to a great extent by careful patient selection and
selecting suitable fractionation schedules. Similarly the inci-
dence of osteoradionecrosis has ranged in literature from
8% to 11% [5,6]. Other severe toxicities associated may be
mucosal necrosis, chronic xerostomia, brachial plexopathy,
subcutaneous ﬁbrosis and hypothyroidism. Accelerated caro-
tid artery stenosis, and increased incidence of second malig-
nancy may be seen in such cases. Hoebers et al. in a
retrospective data of 58 reported 43% serious (late) toxicity
PGrade 3. This categorically points to the fact that a deli-
cate balance between effectiveness and toxicity is required
for the practice of reirradiation [49]. However, we must
emphasize that most of the literature present limited absolute
data which must be considered a limitation compared to
actuarial rate and perhaps underestimate the true incidence
of toxicity. A summary of various trials that have evaluated
re-irradiation in recurrent head and neck cancers is given in
Table 1.Please cite this article in press as: Benson R et al. Re-irradiation for head and neck squamous cell carcinoma, J Egyptian Nat Cancer Inst (2016), http://dx.doi.org/
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The median overall survival expected from re-irradiation may
vary from 10 to 12 month, with a 2 year overall survival rang-
ing from 37% to 58% in various reported trials [6,8,14]. The
overall survival may be slightly higher for patients who under-
went re-irradiation in the postoperative setting with a range of
12–16 months [25,34,35]. The 2 year local control that may be
expected from re-irradiation may be in the range 40–64%
[8,14]. Thus a good survival can be achieved along with good
local control in selected patients of head and neck cancer trea-
ted with re-irradiation.Conclusion
The recurrent head and neck cancer has always been consid-
ered a poor prognostic subgroup. Little effort has been made
to look into these patients separately. Hence, the treatment
of these cases has always been made with a palliative intent
and salvage with curative option has rarely been made espe-
cially those with limited volume recurrence occurring after a
long disease free interval. In patients with local recurrence or
loco-regional recurrence surgery should be attempted for best
cure. In cases with high risk feature (margin positive/Extra
capsular extension) consolidation should be done with post-
operative re-irradiation alone or with chemotherapy. Patients
deemed inoperable/unresectable should be considered for re-
irradiation alone or with concurrent chemotherapy with an
expected median survival of 10–12 months.Disclosures
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